Stock Track | Quidel Soars 7.66% Pre-Market as Cost Cuts, Guidance Outweigh Revenue Decline

Stock Track02-13

Quidel Corporation (QDEL) stock surged 7.66% in pre-market trading on Thursday, following the release of its Q4 2024 earnings report and 2025 guidance.

While the company reported a 4% year-over-year decline in Q4 2024 revenue to $708 million, primarily due to lower COVID-19 and flu testing demand, Quidel provided an optimistic outlook for 2025. The company expects revenue to range between $2.6 billion and $2.81 billion, with adjusted EBITDA guidance of $575 million to $615 million, representing a 22% margin.

Quidel's strong pre-market performance can be attributed to its ongoing cost reduction initiatives and the potential for margin improvement. The company is implementing procurement savings and other cost-cutting measures, which are expected to drive adjusted EBITDA margin expansion by 250 basis points in 2025. Additionally, Quidel highlighted positive developments such as the initiation of clinical trials for its Savanna Respiratory Panel and stable growth in its core Labs business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130173435?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130173435","market":"hk","top_or_hot":-1,"title":"Stock Track | Quidel Soars 7.66% Pre-Market as Cost Cuts, Guidance Outweigh Revenue Decline","media":"Stock Track","content":"<p>Quidel Corporation (QDEL) stock surged 7.66% in pre-market trading on Thursday, following the release of its Q4 2024 earnings report and 2025 guidance.</p>\n\n<p>While the company reported a 4% year-over-year decline in Q4 2024 revenue to $708 million, primarily due to lower COVID-19 and flu testing demand, Quidel provided an optimistic outlook for 2025. The company expects revenue to range between $2.6 billion and $2.81 billion, with adjusted EBITDA guidance of $575 million to $615 million, representing a 22% margin.</p>\n\n<p>Quidel's strong pre-market performance can be attributed to its ongoing cost reduction initiatives and the potential for margin improvement. The company is implementing procurement savings and other cost-cutting measures, which are expected to drive adjusted EBITDA margin expansion by 250 basis points in 2025. Additionally, Quidel highlighted positive developments such as the initiation of clinical trials for its Savanna Respiratory Panel and stable growth in its core Labs business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Quidel Soars 7.66% Pre-Market as Cost Cuts, Guidance Outweigh Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Quidel Soars 7.66% Pre-Market as Cost Cuts, Guidance Outweigh Revenue Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Quidel Corporation (QDEL) stock surged 7.66% in pre-market trading on Thursday, following the release of its Q4 2024 earnings report and 2025 guidance.</p>\n\n<p>While the company reported a 4% year-over-year decline in Q4 2024 revenue to $708 million, primarily due to lower COVID-19 and flu testing demand, Quidel provided an optimistic outlook for 2025. The company expects revenue to range between $2.6 billion and $2.81 billion, with adjusted EBITDA guidance of $575 million to $615 million, representing a 22% margin.</p>\n\n<p>Quidel's strong pre-market performance can be attributed to its ongoing cost reduction initiatives and the potential for margin improvement. The company is implementing procurement savings and other cost-cutting measures, which are expected to drive adjusted EBITDA margin expansion by 250 basis points in 2025. Additionally, Quidel highlighted positive developments such as the initiation of clinical trials for its Savanna Respiratory Panel and stable growth in its core Labs business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QDEL","symbol_name":"窥得儿医药","start_time":0,"source_url":"","article_id":"1130173435","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130173435","pubTimestamp":1739457102,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Quidel Corporation  stock surged 7.66% in pre-market trading on Thursday, following the release of its Q4 2024 earnings report and 2025 guidance.While the company reported a 4% year-over-year decline in Q4 2024 revenue to $708 million, primarily due to lower COVID-19 and flu testing demand, Quidel provided an optimistic outlook for 2025. The company expects revenue to range between $2.6 billion and $2.81 billion, with adjusted EBITDA guidance of $575 million to $615 million, representing a 22% m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QDEL":"窥得儿医药"},"translate_title":"由于成本削减和指引超过收入下降，Quidel股票盘前飙升7.66%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QDEL":1},"content_text":"Quidel Corporation (QDEL) stock surged 7.66% in pre-market trading on Thursday, following the release of its Q4 2024 earnings report and 2025 guidance.\nWhile the company reported a 4% year-over-year decline in Q4 2024 revenue to $708 million, primarily due to lower COVID-19 and flu testing demand, Quidel provided an optimistic outlook for 2025. The company expects revenue to range between $2.6 billion and $2.81 billion, with adjusted EBITDA guidance of $575 million to $615 million, representing a 22% margin.\nQuidel's strong pre-market performance can be attributed to its ongoing cost reduction initiatives and the potential for margin improvement. The company is implementing procurement savings and other cost-cutting measures, which are expected to drive adjusted EBITDA margin expansion by 250 basis points in 2025. Additionally, Quidel highlighted positive developments such as the initiation of clinical trials for its Savanna Respiratory Panel and stable growth in its core Labs business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130173435"}